WO2004050106A1 - Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation - Google Patents

Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation Download PDF

Info

Publication number
WO2004050106A1
WO2004050106A1 PCT/CN2002/000868 CN0200868W WO2004050106A1 WO 2004050106 A1 WO2004050106 A1 WO 2004050106A1 CN 0200868 W CN0200868 W CN 0200868W WO 2004050106 A1 WO2004050106 A1 WO 2004050106A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicine
astragalus
radix
ginseng
epimedium
Prior art date
Application number
PCT/CN2002/000868
Other languages
English (en)
French (fr)
Inventor
Hsiaochang Chan
Yulin Gou
Dewi Rowlands
Yiuwa Chung
Original Assignee
Eu Yan Sang (Hong Kong) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eu Yan Sang (Hong Kong) Limited filed Critical Eu Yan Sang (Hong Kong) Limited
Priority to EP02782659A priority Critical patent/EP1462110A4/en
Priority to AU2002349482A priority patent/AU2002349482A1/en
Priority to US10/497,484 priority patent/US20050123629A1/en
Priority to CA002467444A priority patent/CA2467444A1/en
Priority to CNB028301846A priority patent/CN1329065C/zh
Priority to PCT/CN2002/000868 priority patent/WO2004050106A1/zh
Publication of WO2004050106A1 publication Critical patent/WO2004050106A1/zh
Priority to HK06109050A priority patent/HK1086764A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Definitions

  • the invention relates to a medicament for treating menopausal syndrome of women. Specifically, the invention relates to a Chinese patent medicine for treating menopause syndrome prepared by using Chinese herbal medicine as a raw material, and the present invention also relates to a method for preparing the drug. Background technique
  • Menopause syndrome refers to a period of time before and after natural menopause, in which ovarian function declines, causing endocrine system dysfunction, decreased estrogen levels, metabolic disorders, cardiovascular and autonomic nervous system dysfunction, and menstrual disorders. Sweating, nausea, fever, dizziness, tinnitus, palpitations, insomnia, irritability, irritation of the waist and knees, numbness and itchiness of the skin, memory loss, and even mood disorders are evidenced by a series of symptoms related to menopause. Chinese medicine believes that women will reach menopause, as the body gradually transitions from a healthy and balanced to an aging elderly. With the decline of kidney qi, Tiangui will be exhausted, and the two pulses will gradually become deficient.
  • kidney deficiency is the cause of the disease.
  • the kidney is different from the kidney yin and the kidney yang.
  • the independence of the kidney yin and the kidney yang depends on the essence of the metamorphosis of the spleen and stomach in the day after tomorrow. Speed, elimination or mitigation of evidence before and after the break is crucial. Therefore, in addition to nourishing the kidney in the treatment of the law, attention should also be paid to conditioning the spleen and stomach, invigorating qi and blood, and appropriately relieving liver and stagnation, and regulating emotions.
  • CN1110164A discloses a medicament for treating menopausal syndrome in women. Its composition contains Siwu decoction (Angelica, Shudi, Baiji, Chuanxiong), Sijunzi decoction (Red Ginseng, Poria, Licorice-Lakubai) and contains the basics of Xiaoyao San Drugs (Chaihu, Baiji, Angelica, Poria, Licorice) as well as Epimedium and Astragalus. "New Chinese Medicine", 1988, 20 (9) discloses a medicine for treating menopause of women.
  • Xiaoyao Sanhe Ganmai Dazao Decoction which contains Siwu Decoction (Danggui, Shudi, Baizhu-Qichuanxiong), Sijunzi Decoction (Dangshen, Poria, Licorice, Atractylodes macrocephala), Xiaoyao San's essential medicines (Chaihu, Baiji, Angelica, Poria, Atractylodes, Licorice) and Astragalus and Ophiopogon "New Chinese Medicine", 1988, 26 (12) also discloses a drug for treating menopause of women.
  • the drug composition contains Epimedium, Ophiopogon,
  • the present invention is directed to the deficiency of qi and blood in menopause syndrome, the deficiency of kidney yang, kidney yin, yin deficiency, and liver qi stagnation, and sees menstrual disorders, sometimes chills, dizziness, tinnitus, backache, fatigue, upset, irritability, and abnormal mood , Eat less body fatigue, thoracic rib discomfort and other symptoms.
  • the main treatment method is to nourish qi and blood, and tonify yin and kidney, and relieve liver qi. This side consists of Xiaoyao San, Bazhen Decoction and Erxian Decoction.
  • Efficacy tonify qi and blood, regulate yin and yang, relieve stagnation of liver and stagnation, and relieve kidney fire Fang Zhong re-used Sijunzi Decoction (ginseng, atractylodes, tea, licorice) and Astragalus to replenish qi and strengthen the spleen, and re-used Siwu Decoction (Angelica, Shudi, Baiji, Chuanxiong) to replenish blood and regulate menstruation.
  • the effect of nourishing qi and nourishing blood is to cure the deficiency of qi and blood; then Epimedium and Xianmao are used to warm kidney yang, Ligustrum lucidum and Ophiopogon are used to nourish kidney yin. Reach the effect of reconciling yin and yang; Shaozuo Huangbai relieves the stagnation of liver qi by the deficiency fire caused by diarrhea and kidney yin deficiency. Combination of various medicines, so that qi and blood filling, yin and yang, liver qi is smooth, red and red tone, menopausal evidence can be cured.
  • the present invention is similar to the comparative literature CN1110164A.
  • composition of the present invention is greatly different. Among the six flavors of the present invention, there are differences between them. They are Ophiopogon lucidum, Ligustrum lucidum, Atractylodes chinensis, Cork, Mint and Curculigo. Summary of the Invention
  • the purpose of the present invention is to provide a treatment for the decline of ovarian function, causing endocrine system dysfunction, decreased estrogen levels, metabolic disorders, cardiovascular and autonomic nervous system dysfunction and menstrual disorders, heat sweat, nausea and fever , Dizziness, tinnitus, palpitations, insomnia, irritability, irritability, waist and knee aches, numbness of the skin, itching, loss of memory, and even emotional disorders.
  • One aspect of the present invention is to provide a medicament for treating menopausal syndrome in women, which is characterized in that it is a medicament made of raw materials containing the following weight ratio
  • the two programs of the female Huang Baiming Huang are to further provide drugs for treating menopausal syndrome in women: Bai Shen Qi Qi Zhen
  • Another aspect of the present invention is to further provide a medicine for treating menopausal syndrome in women, wherein the weight ratio of the raw materials is
  • the medicament of the present invention can be used in any of the oral dosage forms described in pharmacy.
  • the specific dosage form of the medicine can be a tablet, granule, pill, powder, hard gel tincture, soft gel tincture, tincture, lozenge, or oral liquid.
  • the preparation method of the preparation may be a method generally used in the art.
  • Another object of the present invention is to provide a method for preparing the medicine for treating menopausal syndrome in women.
  • the drug is available in any of the above three formulations.
  • the method specifically includes: 1. Ophiopogon is reconstituted after cooking; Paeonia lactiflora needs to be cleaned with a high-speed spray gun; ginseng is independently ground, and the remaining medicinal materials are crushed after being processed by traditional Chinese medicine processing methods.
  • each prepared medicinal material is mixed with an appropriate amount of wine, vinegar, ginger, salt and other auxiliary materials, and then cooked in a pressure cooker.
  • the oral preparation can be prepared by using a mixture of the above medicine powders and adding a certain proportion of auxiliary materials.
  • the medicament of the present invention can restore the function of the neuroendocrine system in elderly animals, leading to the restoration of endogenous estrogen production, thereby alleviating or reducing the symptoms (i.e. neurological symptoms, bone mass) caused by impaired estrogen production during menopause. loose).
  • the medicament of the present invention can lower blood lipids, and some of its components have been found to have antiplatelet and muscle relaxation effects. Taken together, these effects can improve cardiovascular function.
  • the medicine of the present invention shows a restoring effect on the immune function of adult animals, suggesting that it has a beneficial effect on the immune system.
  • the medicament of the present invention and its ingredients were found to stimulate colonic secretion, indicating its effect on the digestive system.
  • Preliminary clinical tests have confirmed that daily administration of the drug (300 mg / kg po) over a period of 4 to 8 weeks can improve the symptoms shown by menopausal women to some extent.
  • Fig. 1 is a bar graph showing the effect of a drug of the present invention on serum estrogen levels in aged SD rats.
  • Figure 2 is a bar graph showing the effect of a drug of the present invention on serum progesterone levels in aged female SD rats.
  • Fig. 3 is a bar graph showing the effect of the drug of the present invention on serum ⁇ -endorphin levels in aged female SD rats.
  • Fig. 4 is a bar graph showing the effect of the drug of the present invention on substance P levels in elderly female SD rats.
  • Fig. 5 is a bar graph showing the weight of the sexual organs and pituitary of aged female SD rats after treatment with the drug (3g / kg) of the present invention.
  • Fig. 6 is a photograph showing follicular development in the ovary of aged female SD rats treated with the medium.
  • Fig. 7 is a photograph showing follicular development in the ovary of aged female SD rats treated with the drug (3g / kg) of the present invention. Increased follicles are indicated by arrows.
  • Fig. 8 is a bar graph showing the estrus index of aged female SD rats treated with a median shield during the two 6-day periods before treatment and during the three 6-day periods after treatment.
  • Fig. 9 is a bar chart showing the estrus index of elderly female SD rats treated with the drug of the present invention (6 g / kg) in the interval of two 6 days before the treatment and in the interval of three 6 days after the treatment.
  • Fig. 10 is a graph showing the effect of the drug of the present invention on ADP-induced platelet aggregation. detailed description
  • the Ophiopogon is cooked beforehand and then formulated; the white peony is cleaned with a high-speed spray gun. Ginseng was ground separately and passed through an 80 mesh screen. The remaining medicinal materials are processed by traditional methods of traditional Chinese medicine. Crush into 1 cm 3 size.
  • each processed medicinal material is crushed to a size of 1 cm 3 , and then mixed with an appropriate amount of wine, vinegar, ginger, salt and other auxiliary materials, and then mixed with a pressure cooker.
  • the pressure cooker temperature is controlled to 100 V, and the cooking time is 1 hour.
  • the medicinal materials were dried uniformly at 80 ° C in a conveyor drying oven. After drying, the powder was milled using an air duct grinding device, passed through a 80 mesh sieve using a ternary vibrating screen, and then mixed into the same mesh. Ginseng powder.
  • the mixture of the above medicinal powders is mixed with a pre-prepared honey water (7: 3 for honey: pure water) at a ratio of 7: 3, and then a honey pill is prepared by using a plodder and a pill making machine.
  • the skin was then epithelialized and dried at 80 ° C.
  • Example 7 Effect of the medicine of the present invention on the reproductive system of aged female SD rats Oral administration of 18 g of female SD rats ( ⁇ > 7) 3g / kg of the medicine of the present invention for 8 weeks, the animals were sacrificed, and the organs required for the animals were removed .
  • the results showed that the pituitary of rats treated with the drug of the present invention was significantly heavier than that of untreated rats (Fig. 5).
  • Increased follicles indicating follicular development were observed in the nests of rats treated with the drug of the present invention (Figure 7). However, no control was observed ( Figure 6).
  • Example 8 Effect of the drug of the present invention on platelet aggregation induced by ADP
  • the drug of the present invention and its components were screened and tested for the effect of platelet aggregation induced by ADP (15 g / ml).
  • the method was to take rabbit blood and obtain platelet-rich plasma (PRP) after treatment.
  • the platelet aggregation apparatus was used to test the degree of platelet aggregation. Of the 16 components tested, 6 of them had significant anti-platelet aggregation activity.
  • the drug of the present invention has significant antiplatelet aggregation activity (Fig. 10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

一种治疗妇女更年期综合症的药物及其制备方法 技术领域
本发明涉及一种治疗妇女更年期综合症的药物。 具体地说， 涉及一 种以中草药为原料制备的治疗妇女更年期综合症的中成药， 本发明还涉 及该药物的制备方法。 背景技术
更年期综合症是指妇女在自然绝经前后的一段时间内， 出现卵巢功 能衰退， 引起内分泌系统功能失调， 雌激素水平下降， 新陈代谢障碍， 心血管系统、 植物神经系统功能紊乱而出现月经紊乱， 烘热汗出， 恶心 烦热， 头暈耳鸣， 心悸失眠， 烦躁易怒， 腰膝酸痛， 皮肤麻木刺痒， 记 忆力下降， 甚至情志异常等与绝经有关的一系列症状体证。 中医认为妇 女到更年期， 由于机体由健康均衡逐步向衰老的老年过渡， 随着肾气日 衰， 天癸将竭， 冲任二脉逐渐亏虚， 气血日渐不足， 肾的阴阳易失平衡， 进而导致脏腑功能失调， 因而出现上述症状， 称为 "经断前后诸证" 。 因此， 本病的病因病机主要责之于肾， 肾虛为致病之本。 肾有肾阴与肾 阳之别， 肾阴、 肾阳的充盛又有赖于后天脾胃化生的精獨：物质不断补充， 调理脾胃， "补后天以养先天" ， 对延緩肾气衰退之速度、 消除或减轻 经断前后诸证至为关键。 故在治法上除要补腎外， 同时亦应注重调理脾 胃， 补气益血， 并适当疏肝解郁， 调节情志。
CN1110164A公开了一种治疗妇女更年期综合症的药物， 其组成含 有四物汤（当归、 熟地、 白芍、 川芎）、 四君子汤 (红参、 茯苓、 甘草-缺 白术)， 并且含有逍遥散的基本药物 (柴胡、 白芍、 当归、 茯苓、 甘草)以 及淫羊藿和黄芪。 《新中医》, 1988, 20(9)公开了一种治疗妇女更年期的 药物， 它以逍遥散合甘麦大枣汤组成， 其中含有四物汤（当归、 熟地、 白 芍 -缺川芎)、 四君子汤 (党参、茯苓、甘草、 白术)、逍遥散的基本药物 (柴 胡、白芍、当归、茯苓、白术、甘草)以及黄芪和麦冬。《新中医》, 1988, 26(12) 还公开了一种治疗妇女更年期的药物， 该药物组成含有淫羊藿、 麦冬、
确 认本 女贞子、 白术、 党参、 仙茅。
本发明所针对的是更年期综合症中属于气血不足， 肾阳肾阴倶虚， 肝气郁结所致， 而见月经紊乱， 时而畏寒， 时而头晕耳鸣， 腰酸乏力， 心烦易怒， 情志异常， 食少体倦， 胸肋不舒等症。 治法上重点以大补气 血为主， 并补肾阴肾阳， 疏解肝气。 本方由逍遥散、 八珍汤和二仙汤三 方加减组成。 功效补气血、 调阴阳、 疏肝郁、 泻肾火。 方中重用四君子 汤 (人参、 白术、 茯茶、 甘草)、 黄芪以补气健脾， 并重用四物汤（当归、 熟地、 白芍、 川芎）以补血调经， 两方合用即八珍汤， 共起补气益血之效， 以治气血不足之证； 再以淫羊藿、 仙茅以温补肾阳， 女贞子、 麦冬以滋 养肾阴， 四药合用， 添阴补阳， 以达调和阴阳之效； 少佐黄柏以泻肾阴 虚引致之虚火、 柴胡、 薄荷以疏解肝气之郁结。 诸药合用， 使气血充， 阴阳和， 肝气畅， 冲任调， 更年期诸证自可痊愈。 本发明与相近的对比 文献 CN1110164A组成上有较大差异， 其中本发明有六味药与其不同， 它们是麦冬、 女贞子、 白术、 黄柏、 薄荷、 仙茅。 发明内容
本发明的目的是提供一种具有治疗卵巢功能衰退， 引起内分泌系统 功能失调， 雌激素水平下降， 新陈代谢障碍， 心血管系统、 植物神经系 统功能紊乱而出现月经紊乱， 烘热汗出， 恶心烦热， 头晕耳鸣， 心悸失 眠， 烦躁易怒， 腰膝酸痛， 皮肤麻木刺痒， 记忆力下降， 甚至情志异常 等与绝经有关的一系列症状的妇女更年期综合症的作用的药物。
本发明的一个方案是提供治疗妇女更年期综合症的药物， 其特征在 于它是由包含下述重量配比的原料制成的药剂
人参 3.00-3.52 当归 6.78-7.96
黄芪 11.62-13.64 麦冬 4.31-5.05
女贞子 4.31-5.05 白术 4.31-5.05
白芍 5.56-6.52 茯苓 6.78-7.96
白 4.31-5.05 川芎 5.56-6.52
甘草 4.31-5.05 柴胡 5.56-6.52 熟地 11.62-13.64 淫羊藿 6.78-7.96
薄荷 2.54-2.98 仙茅 4.64-5.44。
本发人黄女黄白明的笫二个方案是进一步提供治疗妇女更年期综合症的药物: 柏参芍芪贞
它是由包含下子述重量配比的原料制成的药剂
人参 3.00-3.52 当归 6.78-7.96
黄芪 9.78-11.48 麦冬 4.31-5.05
女贞子 4.31- 5.05 白术 3.40-3.98
白芍 5.56-6.52 茯苓 4.94-5.80
黄柏 4.32- 5.06 3.72-4.36
甘草 3.40-3.99 柴茯^川白当.胡 5.56-6.52
茶冬术芎归
熟地 11.62-13.64 淫羊藿 6.78-7.96
2.54-2.98 仙茅 4.64-5.44
知母 3.68-4.32 墨旱莲 3.68-4.32。
本发明的又- -个方案是进一步提供治疗妇女更年期综合症的药物， 其中原料的重量配比是
3.26 7.37
12.63 4.69
4.69 4.69
6.04 7.37
4.69 6.04
甘草 4.69 柴胡 6.04
熟地 12.63 淫羊藿 7.37
薄荷 2.76 仙茅 5.04
本发明的药物可以采用任何一种药剂学上所述的口服剂型。 所述药 剂的具体剂型可以是片剂、 颗粒剂、 丸剂、 散剂、 硬胶嚢剂、 软胶嚢剂、 酏剂、 锭剂或口服液。 所述制剂的制备方法可以是本领域通常采用的方 法。
本发明的另一个目的是提供该治疗妇女更年期综合症的药物的制备 方法。 该药物采用以上三个配方中的任何一个。.该方法具体包括： 1. 麦冬经蒸煮后再配方； 白芍需要采用高速喷枪清洗； 人参独立 研磨， 其余药材采用中药传统炮制方法炮制后粉碎。
2. 除人参外， 各炮制后药材配以适量酒、 醋、 姜、 盐等辅料一起 混合后， 采用压力锅蒸煮。
3. 蒸煮后， 将药材于 40 - 80°C烘干； 烘干后， 磨粉， 过 80目筛， 再混入同样目数的人参粉。
4. 利用以上药粉的混合物， 加入一定比例的水和蜂蜜制备水蜜丸。 此外， 采用以上药粉的混合物， 加入一定比例的辅料可以制备所述 口服制剂。
通过一系列的药理学实验证明了本发明药物的安全性和药理学活 性。
急性口服毒性实验证明， 该药物的 LD5。大于 9000mg/kg, 这是雌性 Sprague Dawley (SD) 大鼠一天口服的最大剂量， 相当于人通常口服剂量 的大约 30倍。 亚急性口服毒性实验证明， 在 28天当中， 重复给予以上 品系大鼠 3000mg/kg本发明药物没有观察到任何一只大鼠死亡或者表现 出任何毒性症状。
用本发明药物治疗后， 在老年动物中观察到雌激素水平的明显提 高。
在老年动物的卵巢中观察到改善的卵泡的形成。
采用本发明药物治疗后， 老年动物中垂体尺寸以及重量再次增加。 以上结果提示， 本发明药物可以恢复老年动物的神经内分泌系统的功 能， 导致恢复内源性雌激素的产生， 从而緩解或者减轻由于更年期雌激 素产生受损引起的症状 (即神经性症状、 骨质疏松)。
本发明药物可以降低血脂， 它的一些成分被发现具有抗血小板和肌 肉松弛作用。 总之， 这些作用可以改善心血管功能。
本发明药物显示对于成年动物免疫功能的恢复作用， 提示其对于免 疫系统具有有益的作用。
发现本发明药物及其成分可以刺激结肠分泌， 表明其对于消化系统 的作用。 初步的临床测试证实了在一段为期 4至 8星期的时间内， 每天给予 本发明药物 (300 mg/kg p.o.)， 可在一定程度上改善更年期妇女显示的征 状。 附图说明
图 1是表示本发明药物对于老年 SD大鼠体内血清雌激素水平的影 响的条图。
图 2是表示本发明药物对于老年雌性 SD大鼠体内血清孕酮水平的 影响的条图。
图 3是表示本发明药物对于老年雌性 SD大鼠体内血清 β-内啡肽水 平的影响的条图。
图 4是表示本发明药物对于老年雌性 SD大鼠体内 Ρ物质水平的影 响的条图。
图 5是表示用本发明药物 (3g/kg)治疗后老年雌性 SD大鼠性器官和 垂体的重量的条图。
图 6是表示用介质治疗的老年雌性 SD大鼠卵巢内卵泡发育的照片。 图 7是表示用本发明药物 (3g/kg)治疗的老年雌性 SD大鼠卵巢内卵 泡发育的照片。 用箭头指示增大的卵泡。
图 8是表示用介盾治疗的老年雌性 SD大鼠在治疗前两个 6天的间 期和在治疗后三个 6天的间期中的发情期指数的条图。
图 9是表示用本发明药物 (6g/kg)治疗的老年雌性 SD大鼠在治疗前 两个 6天的间期和在治疗后三个 6天的间期中的发情期指数条图。
图 10是表示本发明药物对于 ADP诱导的血小板聚集的作用的条 图。 具体实施方式
实施例 1
按以下配比称取原料 (千克)： 人参 3.00 当归 6.78
黄芪 11.62 麦冬 4.31
女贞子 4.31 白术 4.31
白芍 5.56 茯苓 6.78
^白 4.32 川芎 5.56
甘草 4.31 柴胡 5.56
熟地 11.62 淫羊藿 6.78
涛何 2.54 仙茅 4.64.
预先将麦冬蒸煮然后配方； 白芍的清洗采用高速喷枪进行清洗。 将 人参单独研磨并且过 80 目筛。 其余药材采用中药传统炮制方法炮制。 粉碎成 1cm3大小。
除人参外， 各炮制后药材粉碎成 1cm3大小， 然后配以适量酒、 醋、 姜、 盐等辅料一起混合后， 采用压力锅蒸煮， 压力锅之温度控制为 100 V , 另外蒸煮时间为 1小时。
蒸煮后， 将药材采用输送带式烘干炉， 于 80°C均匀烘干； 烘干后， 采用风导管研磨设备磨粉， 利用三元振动筛过 80 目筛， 然后再混入同 样目数的人参粉。
利用以上药粉的混合物 ,与预先制备的蜜糖水 (蜜糖:纯水为 7:3)以 7:3 的比例混合， 再利用压条机和制丸机制备水蜜丸。 然后采用过皮技术上 皮并且于 80°C烘干。
实施例 2
按以下配比称取原料 (千克):
人参 3.52 当归 7.96
黄芪 13.64 麦冬 5.05
女贞子 5.05 白术 5.05
白芍 6.52 茯苓 7.96
黄柏 5.06 川芎 6.52
甘草 5.05 柴胡 6.52
熟地 13.64 淫羊藿 7.96
浮何 2.98 仙茅 5.44。 具体的制备方法与实施例 1相同。
实施例 3
按以下配比称取原料 (千克)：
人参 3.26 当归 7.37 黄芪 12.63 麦冬 4.69 女贞子 4.69 白术 4.69 白芍 6.04 茯苓 7.37 黄柏 4.69 川芎 6.04 甘草 4.69 柴胡 6.04 熟地 12.63 淫羊藿 7.37
)辱啊 2.76 仙茅 5.04, 具体的制备方法与实施例 1相同。
实施例 4 ·
按以下配比称取原料 (千克)：
人参 3.00 当归 6.78 黄芪 9.78 麦冬 4.31 女贞子 4.31 白术 3.40 白芍 5.56 茯答 4.94 黄柏 4.32 川芎 3.72 甘草 3.40 柴胡 5.56 熟地 11.62 淫羊藿 6.78 薄荷 2.54 仙茅 4.64 知母 3.68 墨旱莲 3.68, 具体的制备方法与实施例 1相同。
实施例 5
按以下配比称取原料 (千克)：
人参 3.52 当归 7.96 黄芪 - 11.48 麦冬 5.05 女贞子 5.05 白术 3.98 白芍 6.52 茯苓 5.80
黄柏 5.06 川芎 4.36
甘草 3.99 柴胡 6.52
熟地 13.64 淫羊藿 7.96
；辱何 2.98 仙茅 5.44
知母 4.32 '置、亍连 4.32。
具体的制备方法与实施例 1相同。
实施例 6 本发明药物对于老年雌性 SD大鼠体内血清激素水平的影 响
口服给予 18个月龄雌性 SD大鼠 1.5-6g/kg的本发明药物， 抽血， 分析血样中激素水平的变化， 结果显示本发明药物能够明显增加血清雌 激素水平， 而对照动物没有变化 (图 1)。 以 3g kg-6g kg口服给予 18个月 龄 SD大鼠本发明药物与对照相比也可以降低血清 P物质的水平 (图 4)。 然而， 在给予本发明药物的所有剂量范围内， 血清孕酮 (图 2)和 β-内啡肽 (图 3)均保持不变。
实施例 7 本发明药物对于老年雌性 SD大鼠生殖系统的影响 口服给予 18个月龄雌性 SD大鼠 (η > 7) 3g/kg的本发明药物 8周 , 处死动物， 取出动物体内所需器官。 结果显示用本发明药物治疗大鼠的 垂体明显重于未治疗大鼠的垂体 (图 5)。 在用本发明药物治疗的大鼠的卵 巢内可以观察到表明卵泡发育的增大的卵泡 (图 7)。 然而， 对照没有观察 到（图 6)。 阴道涂片的组织学检查显示用本发明药物治疗的动物与未治疗 的对照动物相比， 具有更高百分比的接近于排卵周期的动情前期或者动 情期特性的细胞 (图 8和 9)。 提示本发明药物对于子宫道的雌激素作用。
实施例 8 本发明药物对于由 ADP诱导的血小板聚集的作用 对本发明药物及其组分进行了对于由 ADP (15 g/ml)诱导的血小板聚集 的作用的筛选和测试。方法是取兔血，经处理后得到富血小板血浆 (PRP), 用血小板聚集仪测试血小板的聚集程度。 在被测试的 16 种组分中， 其 中 6 种组分具有显著的抗血小板聚集活性。 本发明药物具有显著的抗血 小板聚集的活性 (图 10)。

Claims

权 利 要 求 书
1. 一种治疗妇女更年期综合症的药物， 其特征在于它是由包含下 述重量配比的原料制成的药剂
人参 3.00-3.52 当归 6.78-7.96
黄芪 11.62-13.64 麦冬 4.31-5.05
女贞子 4.31-5.05 白术 4.31-5.05
白芍 5.56-6.52 茯茶 6.78-7.96
黄柏 4.31-5.05 川芎 5.56-6.52
甘草 4.31-5.05 柴胡 5.56-6.52
熟地 11.62-13.64 淫羊藿 6.78-7.96
浮何 2.54-2.98 仙茅 4.64-5.44。
2. 根据权利要求 1 所述的治疗妇女更年期综合症的药物， 它是由 包含下述重量配比的原料制成的药剂
人参 3.00-3.52 当归 6.78-7.96
黄芪 9.78-11.48 麦冬 4.31-5.05
女贞子 4.31-5.05 白术 3.40-3.98
白芍 5.56-6.52 茯苓 4.94-5.80
黄柏 4.32-5.06 川芎 3.72-4.36
甘草 3.40-3.99 柴胡 5.56-6.52
熟地 11.62-13.64 淫羊藿 6.78-7.96
/ 、辱何 2.54-2.98 仙茅 4.64-5.44
知母 3.68-4.32 墨旱莲 3.68-4.32。
3. 根据权利要求 1 所述的治疗妇女更年期综合症的药物， 其中原 料的重量配比是
人参 3.26 当归 7.37
黄芪 12.63 麦冬 4.69 女贞子 4.69 白术 4.69
白芍 6.04 夜革 7.37
黄柏 4.69 川芎 6.04
甘草 4.69 柴胡 6.04
熟地 12.63 淫羊藿 7.37
潜何 2.76 仙茅 5氣
4. 根据权利要求 1 - 3 中任一项所述的治疗妇女更年期综合症的药 物， 其特征在于所述药剂是任何一种药剂学上所述的口 艮剂型。
5. 根据权利要求 4 所述的治疗妇女更年期综合症的药物， 其特征 在于所述药剂是片剂、 颗粒剂、 丸剂、 散剂、 硬胶嚢剂、 软胶嚢剂、 酏 剂、 走剂或口 艮液。
6. 根据权利要求 5 所述的治疗妇女更年期综合症的药物， 其中所 述药剂是水蜜丸。
7. 权利要求 6所述的治疗妇女更年期综合症的水蜜丸的制备方法， 其特征在于：
麦冬经蒸煮后再配方； 白芍需要采用高速喷枪清洗； 人参独立研磨， 其余药材采用中药传统炮制方法炮制后粉碎。
除人参外， 各炮制后药材配以适量酒、 醋、 姜、 盐等辅料一起混合 后， 采用压力锅蒸煮。
蒸煮后， 将药材于 40 - 8CTC烘干； 烘干后， 磨粉， 过 80 目筛， 再 混入同样目数的人参粉。
利用以上药粉的混合物， 加入一定比例的水和蜂蜜制备水蜜丸。
8. 根据权利要求 Ί 所述的治疗妇女更年期综合症的水蜜丸的制备 方法， 其中于 80°C烘干。
PCT/CN2002/000868 2002-12-04 2002-12-04 Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation WO2004050106A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP02782659A EP1462110A4 (en) 2002-12-04 2002-12-04 MEDICINAL PRODUCT FOR TREATING CLIMACTERIC SYNDROME IN WOMEN AND METHOD FOR PREPARING THE SAME
AU2002349482A AU2002349482A1 (en) 2002-12-04 2002-12-04 A medicine for treating woman climacteric syndrome and preparation method thereof
US10/497,484 US20050123629A1 (en) 2002-12-04 2002-12-04 Medicine for treating woman climacteric syndrome and preparation method thereof
CA002467444A CA2467444A1 (en) 2002-12-04 2002-12-04 Medicament for treatment of climacteric syndrome of women and preparation method thereof
CNB028301846A CN1329065C (zh) 2002-12-04 2002-12-04 一种治疗妇女更年期综合症的药物及其制备方法
PCT/CN2002/000868 WO2004050106A1 (fr) 2002-12-04 2002-12-04 Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation
HK06109050A HK1086764A1 (en) 2002-12-04 2006-08-15 A medicine for treating woman climacteric syndromeand preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2002/000868 WO2004050106A1 (fr) 2002-12-04 2002-12-04 Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation

Publications (1)

Publication Number Publication Date
WO2004050106A1 true WO2004050106A1 (fr) 2004-06-17

Family

ID=32400064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2002/000868 WO2004050106A1 (fr) 2002-12-04 2002-12-04 Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation

Country Status (7)

Country Link
US (1) US20050123629A1 (zh)
EP (1) EP1462110A4 (zh)
CN (1) CN1329065C (zh)
AU (1) AU2002349482A1 (zh)
CA (1) CA2467444A1 (zh)
HK (1) HK1086764A1 (zh)
WO (1) WO2004050106A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103243006A (zh) * 2012-02-13 2013-08-14 农金宁 一种苗酒配方

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7775983B2 (en) * 2005-09-16 2010-08-17 Cardiac Pacemakers, Inc. Rapid shallow breathing detection for use in congestive heart failure status determination
US20070098671A1 (en) * 2005-11-02 2007-05-03 Martin Gregory D Composition and method of treatment for irritated skin
CN101129448B (zh) * 2006-08-21 2012-04-25 兰州大得利生物化学制药(厂)有限公司 防治更年期综合症和骨质疏松症的组合物及其制备方法
CA2696304A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Estrogenic extracts of ligustrum lucidum ait. of the oleaceae family and uses thereof
CN101244238B (zh) * 2008-02-29 2010-07-14 孙相如 一种治疗更年期综合症的中药组合物
US20090297638A1 (en) * 2008-04-11 2009-12-03 Bionovo, Inc. ESTROGENIC EXTRACTS OF Anemarrhena asphodeloides Bge. from the Liliaceae Family and USES THEREOF
US8489539B2 (en) * 2009-10-05 2013-07-16 Elc Management, Llc Computer-aided diagnostic systems and methods for determining skin compositions based on traditional chinese medicinal (TCM) principles
CN102125286B (zh) * 2010-12-30 2012-07-25 陈慧婷 调理女性月经量过多饮料配方及制备方法
CN102406838B (zh) * 2011-12-06 2013-01-09 赵英霖 一种治疗更年期综合症的中药
CN102670794A (zh) * 2012-05-09 2012-09-19 荣成市商贸城卫生所 一种治疗湿热型盆腔炎的中药组合物
RU2494771C1 (ru) * 2012-07-27 2013-10-10 Наталья Александровна Гладкова Способ лечения климактерического синдрома
FR2997299B1 (fr) * 2012-10-30 2014-12-26 Sederma Sa Association d'extraits de plantes, ingredient actif cosmetique et composition les contenant, et utilisation topique cosmetique
CN103393927B (zh) * 2013-07-26 2015-02-11 张佳奇 一种治疗更年期综合症的药物及其制备方法
CN104001052A (zh) * 2014-06-09 2014-08-27 杨献华 一种治疗更年期综合症的中药组合物
CN104146261B (zh) * 2014-09-02 2015-09-02 王叶颖 一种妇女更年期的中药保健品及其制备方法
CN104800436A (zh) * 2015-04-23 2015-07-29 彭凤芹 一种治疗肾气不固型更年期综合症的中药
CN104922250A (zh) * 2015-05-29 2015-09-23 四川金堂海纳生物医药技术研究所 一种治疗女性更年期综合征的药物及其制备方法
CN104873717A (zh) * 2015-06-30 2015-09-02 周冠旻 一种治疗更年期综合征的中药
CN108030867A (zh) * 2017-12-22 2018-05-15 上海市嘉定区中医医院 一种治疗围绝经期综合征患者的中药组合物
CN109045191B (zh) * 2018-11-01 2021-09-03 上海市北站医院 一种治疗经间期出血疾病的中药组合物及其应用
CN110755565A (zh) * 2019-11-27 2020-02-07 文一兵 一种中药妇康灵根治妇女的更期综合症的配方
CN111588798A (zh) * 2020-03-11 2020-08-28 复旦大学附属妇产科医院 一种改善卵巢功能低下的中药复方制剂及其制备方法
CN112007121B (zh) * 2020-09-16 2022-02-25 长春中医药大学附属医院(吉林省中医院) 治疗绝经综合征的口服冲剂及其制备工艺
CN113134058A (zh) * 2021-04-30 2021-07-20 齐万琴 一种治疗女性更年期综合症的中药组合物及其制备方法
CN115252700B (zh) * 2022-07-27 2023-07-11 佛山市高明区人民医院 用于治疗颈源性耳鸣的中药组合物、药物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072855A (zh) * 1992-12-02 1993-06-09 杨晶珠 防治更年期综合症药剂的制备方法
CN1110164A (zh) * 1994-04-08 1995-10-18 沈阳市新北制药厂 续春冲剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874084A (en) * 1996-07-19 1999-02-23 Yng-Wong; Quing Non Using complex herbal formulations to treat hot flashes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072855A (zh) * 1992-12-02 1993-06-09 杨晶珠 防治更年期综合症药剂的制备方法
CN1110164A (zh) * 1994-04-08 1995-10-18 沈阳市新北制药厂 续春冲剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1462110A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103243006A (zh) * 2012-02-13 2013-08-14 农金宁 一种苗酒配方

Also Published As

Publication number Publication date
AU2002349482A1 (en) 2004-06-23
EP1462110A1 (en) 2004-09-29
CA2467444A1 (en) 2004-06-04
EP1462110A4 (en) 2004-10-20
CN1735421A (zh) 2006-02-15
CN1329065C (zh) 2007-08-01
HK1086764A1 (en) 2006-09-29
US20050123629A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
WO2004050106A1 (fr) Produit medicinal servant a traiter le syndrome climacterique chez la femme et sa methode de preparation
CN101468171B (zh) 一种肥者减肥、瘦者长肉的药物
CN104667070A (zh) 一种治疗皮肤病的药物及其制备方法
CN104984297A (zh) 一种药物组合物在制备治疗闭经药物中的用途
CN104922613A (zh) 一种治疗不孕不育症的药物组合物及其制备方法
CN102813857A (zh) 一种中药丝萸养血益肾制剂
CN105288537A (zh) 一种治疗女性更年期综合症的药物组合物及其制备方法
CN104524159A (zh) 一种治疗乳腺增生的药物组合物
CN104524478A (zh) 一种治疗闭经的外用中药制剂及其制备方法
CN104491802A (zh) 一种中药制剂在制备治疗急慢性胃炎药物中的用途
CN104225166A (zh) 一种治疗闭经的中药组合物及其制备方法
CN103285329B (zh) 一种治疗妇女痛经的药物及其制备方法
CN104984296A (zh) 一种治疗女性更年期综合症的药物组合物及其制备方法
CN105796845A (zh) 药物组合物在制备治疗女性更年期综合征药物中的用途
CN105797081A (zh) 一种治疗闭经的药物组合物
CN103520421A (zh) 一种治疗狐臭的中药组合物
CN106110108A (zh) 一种治疗慢性肝炎的苗药
CN105362630A (zh) 一种治疗更年期综合症的药物组合物及其制备方法
CN105169338A (zh) 一种治疗女性更年期综合症的药物组合物及其制备方法
CN105770673A (zh) 一种含艾叶的中药制剂用于制备治疗慢性胃炎药物中的用途
CN104958662A (zh) 治疗脂肪性肝炎合并高脂血症的中药组合物及其制备方法
CN105213511A (zh) 一种药物组合物用于制备治疗闭经药物中的用途
CN105126022A (zh) 一种治疗鱼鳞病的药物及其制备方法
CN114712470B (zh) 一种治疗男士肾亏的药物及其制备方法
CN105362966A (zh) 一种制备治疗脂肪肝的中药制剂的方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2002782659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002349482

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2467444

Country of ref document: CA

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2002782659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10497484

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 20028301846

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWR Wipo information: refused in national office

Ref document number: 2002782659

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002782659

Country of ref document: EP